keyword
https://read.qxmd.com/read/34076848/hypervigilance-allostatic-load-and-migraine-prevention-antibodies-to-cgrp-or-receptor
#1
REVIEW
Andrew Blumenfeld, Paul L Durham, Alexander Feoktistov, Debbie L Hay, Andrew F Russo, Ira Turner
Migraine involves brain hypersensitivity with episodic dysfunction triggered by behavioral or physiological stressors. During an acute migraine attack the trigeminal nerve is activated (peripheral sensitization). This leads to central sensitization with activation of the central pathways including the trigeminal nucleus caudalis, the trigemino-thalamic tract, and the thalamus. In episodic migraine the sensitization process ends with the individual act, but with chronic migraine central sensitization may continue interictally...
June 2, 2021: Neurology and Therapy
https://read.qxmd.com/read/34048395/preventive-migraine-treatment
#2
Rebecca Burch
PURPOSE OF REVIEW: This article provides an overview of preventive interventions for migraine, including when to start and how to choose a treatment, pharmacologic options (both older oral treatments and new monoclonal antibodies to calcitonin gene-related peptide [CGRP] or its receptor), nonpharmacologic treatment such as neuromodulation, and preventive treatment of refractory migraine. RECENT FINDINGS: The migraine preventive treatment landscape has been transformed by the development of monoclonal antibodies targeting CGRP or its receptor...
June 1, 2021: Continuum: Lifelong Learning in Neurology
https://read.qxmd.com/read/34003147/ditans-vs-gepants-a-systematic-review-and-indirect-network-meta-analysis-for-comparative-analysis-of-efficacy-and-safety
#3
Alok Singh, Dhyuti Gupta, Abhishek Singh
Background: An acute attack of migraine, incapacitates the migraineurs, and is widely prevalent. And to warden off its symptoms, recently two groups of drugs have been approved and launched. Objective: The aim of this systematic review and indirect meta-analysis is to evaluate and summarize the effectiveness of these pharmacological interventions in managing the aforesaid disease. Material and Methods: An extensive literature search was done through Cochrane library, Pub Med, clincialtrials...
March 2021: Neurology India
https://read.qxmd.com/read/34003146/acute-treatment-of-migraine-what-has-changed-in-pharmacotherapies
#4
REVIEW
Chun-Pai Yang, Kuo-Ting Huang, Ching-Mao Chang, Cheng-Chia Yang, Shuu-Jiun Wang
Background: Migraine is the most prevalent neurological disorder and the leading cause of disability in individuals under 50 years of age. Two types of migraine therapies have been defined: acute therapy (abortive or symptomatic treatment), the purpose of which is to interrupt migraine attacks, and preventive treatment (prophylactic treatment), the purpose of which is to reduce the frequency and severity of migraine attacks. Objective: This paper reviews research advances in new agents for acute therapy of migraine...
March 2021: Neurology India
https://read.qxmd.com/read/33974014/diagnosis-and-management-of-headache-a-review
#5
REVIEW
Matthew S Robbins
Importance: Approximately 90% of people in the US experience headache during their lifetime. Migraine is the second leading cause of years lived with disability worldwide. Observations: Primary headache disorders are defined as headaches that are unrelated to an underlying medical condition and are categorized into 4 groups: migraine, tension-type headache, trigeminal autonomic cephalalgias, and other primary headache disorders. Studies evaluating prevalence in more than 100 000 people reported that tension-type headache affected 38% of the population, while migraine affected 12% and was the most disabling...
May 11, 2021: JAMA
https://read.qxmd.com/read/33916043/cgrp-receptor-antagonists-and-5-ht1f-receptor-agonist-in-the-treatment-of-migraine
#6
REVIEW
Matilde Capi, Valerio De Angelis, Donatella De Bernardini, Ottavia De Luca, Fabiola Cipolla, Luana Lionetto, Maurizio Simmaco, Paolo Martelletti
Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex pathophysiology of migraine has allowed us to make great strides in the development of new approaches for acute and preventive treatment. This evidence has led to the development of small molecules antagonist molecules of the CGRP receptor ("gepants") and of a new class of medications called "Ditans". This review presents the data from clinical trials reporting the efficacy, safety, and tolerability of the new drugs used in the treatment of migraines...
April 1, 2021: Journal of Clinical Medicine
https://read.qxmd.com/read/33874756/safety-and-efficacy-of-ubrogepant-in-participants-with-major-cardiovascular-risk-factors-in-two-single-attack-phase-3-randomized-trials-achieve-i-and-ii
#7
Susan Hutchinson, Stephen D Silberstein, Andrew M Blumenfeld, Richard B Lipton, Kaifeng Lu, Sung Yun Yu, Lawrence Severt
OBJECTIVE: To examine the safety and efficacy of ubrogepant for acute treatment of migraine across cardiovascular (CV) disease risk categories. METHODS: ACHIEVE I and II were multicenter, double-blind, single-attack, phase 3 trials in adults with migraine, with or without aura. Participants were randomized 1:1:1 to placebo or ubrogepant (50 or 100 mg in ACHIEVE I; 25 or 50 mg in ACHIEVE II), to treat one migraine attack of moderate or severe headache pain intensity...
April 19, 2021: Cephalalgia: An International Journal of Headache
https://read.qxmd.com/read/33824219/-gepants-and-ditans
#8
Hisanori Kowa
The calcitonin gene-related peptide (CGRP) has been shown to play a major role in the pathophysiology of migraine in recent years. Studies have suggested that blocking CGRP signaling is an effective preventive and therapeutic strategy in patients with migraine. Triptans, considered the mainstay of antimigraine treatment cause vasoconstriction; however, gepants and ditans (two novel classes of therapeutic agents) inhibit CGRP release but do not show a vasoconstrictor effect. Both these drugs are awaiting clinical approval in Japan as antimigraine medications that can be administered to patients with cardiovascular risk factors and to those with triptan-refractory migraine...
April 2021: Brain and Nerve, Shinkei Kenkyū No Shinpo
https://read.qxmd.com/read/33749470/deprescribing-in-migraine
#9
EDITORIAL
Paolo Martelletti, Michelangelo Luciani, Valerio Spuntarelli, Enrico Bentivegna
No abstract text is available yet for this article.
March 20, 2021: Expert Opinion on Drug Safety
https://read.qxmd.com/read/33709972/medication-overuse-headache
#10
Mark W Green
PURPOSE OF REVIEW: Medication overuse headache (MOH)is a disabling problem worldwide with areas of controversy regarding its cause. This article reviews the recent ideas regarding the development of this disorder and its effective management. RECENT FINDINGS: It has been proposed that all acute migraine medications can lead to MOH, with differences in the propensity of different agents to cause the problem. Early data suggests that gepants, which are small-molecule calcitonin gene-related peptide antagonists used for the acute treatment of migraine, may be an exception...
March 11, 2021: Current Opinion in Neurology
https://read.qxmd.com/read/33648385/evaluating-rimegepant-for-the-treatment-of-migraine
#11
Tessa de Vries, Linda Al-Hassany, Antoinette MaassenVanDenBrink
Introduction Calcitonin gene-related peptide (CGRP) is a vasodilatory neuropeptide involved in the pathophysiology of migraine, a highly disabling neurovascular disorder characterized by severe headache attacks. Rimegepant is a small-molecule CGRP receptor antagonist approved by the FDA for acute treatment of migraine and currently under investigation for migraine prophylaxis. Areas covered The authors summarize available data on safety and tolerability of rimegepant and provide insights on its use for acute migraine treatment...
March 10, 2021: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/33633424/lasmiditan-for-the-treatment-of-migraines-with-or-without-aura-in-adults
#12
REVIEW
Amnon A Berger, Ariel Winnick, Daniel Popovsky, Alicia Kaneb, Kevin Berardino, Adam M Kaye, Elyse M Cornett, Alan D Kaye, Omar Viswanath, Ivan Urits
Migraines are a common form of primary headache, affecting women more than men (17.4% and 5.7% of US population, respectively, a total of 12%) that carry significant morbidity and disability, as well as a hefty healthcare price tag. They are most prevalent in women of reproductive ages and are estimated to be the 6th disease in order of causing global burden. They are estimated to cause 45.1 million years lived with disability, or 2.9% of global years lost to disability. Migraine treatment divides into acute, abortive treatment for relief of an ongoing migraine attack, and prophylactic therapy to reduce the occurrence of migraines, specifically for patients suffering from chronic and frequent episodic migraines...
October 15, 2020: Psychopharmacology Bulletin
https://read.qxmd.com/read/33626922/migraine-therapeutics-differentially-modulate-the-cgrp-pathway
#13
Minoti Bhakta, Trang Vuong, Tetsuya Taura, David S Wilson, Jennifer R Stratton, Kimberly D Mackenzie
BACKGROUND: The clinical efficacy of migraine therapeutic agents directed towards the calcitonin-gene related peptide (CGRP) pathway has confirmed the key role of this axis in migraine pathogenesis. Three antibodies against CGRP - fremanezumab, galcanezumab and eptinezumab - and one antibody against the CGRP receptor, erenumab, are clinically approved therapeutics for the prevention of migraine. In addition, two small molecule CGRP receptor antagonists, ubrogepant and rimegepant, are approved for acute migraine treatment...
February 24, 2021: Cephalalgia: An International Journal of Headache
https://read.qxmd.com/read/33608814/ubrogepant-for-the-acute-treatment-of-migraine-pooled-efficacy-safety-and-tolerability-from-the-achieve-i-and-achieve-ii-phase-3-randomized-trials
#14
Susan Hutchinson, David W Dodick, Christina Treppendahl, Nathan L Bennett, Sung Yun Yu, Hua Guo, Joel M Trugman
INTRODUCTION: Ubrogepant is an oral, small-molecule calcitonin gene-related peptide receptor antagonist approved for the acute treatment of migraine. The efficacy and safety of ubrogepant were demonstrated in two pivotal phase 3, single-attack, randomized, placebo-controlled trials (ACHIEVE I and ACHIEVE II). METHODS: We conducted a post hoc analysis of pooled data from the ACHIEVE trials to evaluate the efficacy, safety, and tolerability of ubrogepant 50 mg (the only dose evaluated in both trials) versus placebo across a large population of participants with migraine...
February 20, 2021: Neurology and Therapy
https://read.qxmd.com/read/33608115/rational-use-of-lasmiditan-for-acute-migraine-treatment-in-adults-a-narrative-review
#15
REVIEW
Anna Ferrari, Cecilia Rustichelli
PURPOSE: This narrative review provides an update on the research that led to the development of ditans and lasmiditan for the acute treatment of migraine in adults and discusses the potential advantages and disadvantages of lasmiditan in clinical use. METHODS: The electronic databases PubMed, Scopus, and ClinicalTrials.gov were searched from database inception through January 9, 2021, to identify relevant studies. Search results were assessed for their overall relevance to this review...
February 16, 2021: Clinical Therapeutics
https://read.qxmd.com/read/33550872/rimegepant-acute-treatment-for-migraine-headaches
#16
Golden L Peters, Erin K Hennessey
Migraine headache treatment is quickly evolving. There have been three new acute migraine treatment options (i.e., lasmiditan, rimegepant, ubrogepant) and four new preventive migraine treatment options (i.e., erenumab, fremanezumab, galcanezumab, eptinezumab) released in the past 3 years. The new migraine treatments are focusing on pathways within the newly, better understood neurovascular hypothesis that further describes the pathophysiology of migraine headaches in more detail than before. The discovery of vasoactive peptides, such as calcitonin gene-related peptide, has led to the development of many of these migraine agents...
May 2021: Pain Management
https://read.qxmd.com/read/33369482/novel-synthetic-treatment-options-for-migraine
#17
Andrea Negro, Paolo Martelletti
Introduction : Migraine is one of the most common neurological disorders. Nowadays, the 5-HT1B/1D receptor agonists, namely triptans, are considered as the standard of care for migraine acute treatment. However, triptans have limitations in some patients, such as incomplete pain relief, headache recurrence, and cardiovascular contraindications. New 5-HT1F receptor agonists, namely ditans, and calcitonin gene-related peptide receptor antagonists, namely gepants, have been developed as migraine-specific treatments...
December 28, 2020: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/33332483/rimegepant-for-the-treatment-of-migraine
#18
A Negro, P Martelletti
Rimegepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist developed with a novel quick-dissolve oral tablet formulation for the acute treatment of migraine by Biohaven Pharmaceuticals, under license from Bristol Myers Squibb. The completed phase II and III trials showed its efficacy in terms of pain freedom, pain relief, release of migraine symptoms and lifestyle recovery, with an effect sustained up to 48 h. Significant clinical efficacy has been reported with a rimegepant single dose...
December 2020: Drugs of Today
https://read.qxmd.com/read/33287305/pharmacokinetics-pharmacodynamics-and-drug-drug-interactions-of-new-anti-migraine-drugs-lasmiditan-gepants-and-calcitonin-gene-related-peptide-cgrp-receptor-monoclonal-antibodies
#19
REVIEW
Danuta Szkutnik-Fiedler
In the last few years, there have been significant advances in migraine management and prevention. Lasmiditan, ubrogepant, rimegepant and monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) are new drugs that were launched on the US pharmaceutical market; some of them also in Europe. This publication reviews the available worldwide references on the safety of these anti-migraine drugs with a focus on the possible drug-drug (DDI) or drug-food interactions. As is known, bioavailability of a drug and, hence, its pharmacological efficacy depend on its pharmacokinetics and pharmacodynamics, which may be altered by drug interactions...
December 3, 2020: Pharmaceutics
https://read.qxmd.com/read/33223077/update-on-calcitonin-gene-related-peptide-antagonism-in-the-treatment-of-migraine
#20
REVIEW
Edoardo Caronna, Amaal J Starling
The discovery of calcitonin gene-related peptide (CGRP) and its role in migraine has promoted a new era in migraine treatment: CGRP antagonism. Two classes of medications are currently available: small molecules targeting the CGRP receptor and monoclonal antibodies targeting the CGRP receptor or CGRP ligand. The revolution of these medications is represented by blurring the borders between acute and preventive treatments, episodic and chronic migraine, naïve and refractory patients and even between migraine and other headache disorders...
February 2021: Neurologic Clinics
keyword
keyword
66658
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"